uncontrolled evidence
play

Uncontrolled evidence in rare cancers Paolo G. Casali - PowerPoint PPT Presentation

Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it R Eur Eur J C J Can ance cer 201 r 2011;47 1;47:249 :2493 Clinical decision-making Methods to combine evidence New study designs


  1. Uncontrolled evidence in rare cancers Paolo G. Casali paolo.casali@istitutotumori.mi.it

  2. R

  3. Eur Eur J C J Can ance cer 201 r 2011;47 1;47:249 :2493

  4. Clinical decision-making  Methods to combine evidence  New study designs  Surrogate end points  Organization of studies 

  5. Prospective clinical data bases

  6. «Big clinical data»…

  7. Phase I  MTD dose! activity! Phase II Phase III  OR  OS efficacy!  QoL standard

  8. Lung cancer Boolell V et al. Cancers 2015;71815

  9. Soft tissue sarcomas & GIST …….

  10. STS: advanced disease ADM 75 mg/sqm R ADM 75 mg/sqm + IFX 7.5 g/sqm EORTC Soft Tissue & Bone Sarcoma Group

  11. La Lanc ncet et On Onco col l 20 2014 14;15:41 ;15:415

  12. J Clin Oncol 2015;Epub

  13. Mol Cancer Therap 2009;8:449

  14. Van an Der er Gra Graaf af WTA WTA et et al, al, La Lanc ncet et 20 2012 12;379 ;379:187 :1879

  15. Van an Der er Gra Graaf af WTA WTA et et al, al, La Lanc ncet et 20 2012 12;379 ;379:187 :1879

  16. Italiano A et al. Patterns of care and outcome of patients (pts) with metastatic soft-tissue sarcoma (STS) according to histological subtype and treatment setting: The METASTAR study. ASCO Ann. Meet. 2016, #11014

  17. Leiomyosarcoma ADM GEM TRB DTIC PAZO

  18. t T response progression

  19. Tumor response as a surrogate

  20. Quality of life -% ?

  21. Quality of life -% ?

  22. Survival… -% ?

  23. BMJ 2003;327:1459

  24. N N Eng Engl l J M J Med ed 198 1987;31 7;316:25 6:250

  25. GIST: tumor response

  26. GIST: tumor response Choi’s 10% 15%

  27. Choi’s RECIST

  28. -13 HU 9 HU 15 HU 36 HU 83 HU - 18 HU -34 HU -9 HU 5 HU 9 HU 52 HU 57 HU - 2 HU 61 HU 3 HU 13 HU 5 HU 20 HU 39 HU 3 HU 10 HU 57 HU

  29. Immune therapies: tumor response Postow MA et al. J Clin Oncol 2015;33:1974

  30. Karnofsky DA, 1961;6:709

  31. Reliability (reproducibility) = !

  32. J Na J Natl tl Can ance cer r In Inst 2 st 200 000;92 0;92:205 :205

  33. J Na J Natl tl Can ance cer r In Inst 2 st 200 000;92 0;92:205 :205

  34. 1. Personalized tool -% ?

  35. 2. Volume

  36. 3. Non-dimensional changes

  37. 4. Temporal dimension t

  38. 5. Continuous variable

  39. 6. Growth rate t

  40. t

  41. Boo ooth th CM et et al. al. Eur J C Eur J Can ance cer r 20 2008 08;44:25 ;44:25

  42. Con ontr troll oll Cli lin n Trials rials 20 2000 00;21:34 ;21:343

  43. Reliability (reproducibility) = !

  44. paolo.casali@istitutotumori.mi.it @casali_pg

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend